LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.
The company, whose main technology is a engineered alternative to antibodies, said it is now in a position to test the TMAC linker in humans "well ahead of its original plans".
TMAC - tumour microenvironment activated drug conjugates - is a new form of cancer immunotheraphy combining affimers with chemotherapies in a single drug using a linker designed to only release the chemotherapy in the tumour microenvironment, Avacta explained.
"What is so attractive about Avacta's Affimer TMAC programme is that it offers a way to combine chemotherapy with immune checkpoint inhibitors without exposing the whole body to the same level of the chemo-toxin," Chief Executive Officer Alastair Smith said.
Avacta shares were trading 6.3% higher at 31.62 pence each.
Avacta Group (AVCT)